ClinicalTrials.gg
TerminatedNCT06119529Updated Oct 3, 2025Results posted

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1 interventional study of LY3872386 and Prednisone in Healthy and Atopic Dermatitis, sponsored by Eli Lilly and Company. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Why this study was terminated
Based on emerging nonclinical data, the study was terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Dermatitis, Atopic by Eli Lilly and Company — 1 open to participants now, 2 under way, 2 of them phase 3. Dermatitis, Atopic · Eli Lilly and Company.

Enrollment
30th of 30
18 · median 283
Started
2023
with 3 others
Phase 1
3 of 30
none open now
Registered
27th of 30
by date

Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 30th largest by enrollment, is one of 4 that started in 2023, is one of 3 in phase 1, and was the 27th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 30 studies in Dermatitis, Atopic by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dermatitis, Atopic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.

03

Conditions studied

  • Healthy
  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A and C:

  • Overtly healthy as determined by medical evaluation

    1. To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, defined as the participant's biological parents and all of the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan
    2. To qualify as Chinese for the purpose of this study, the participant must be, at a minimum, third-generation Chinese, defined as all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
  • Have a of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male participants who agree to use highly effective or effective methods of and women not of may participate in part A and C

Part B:

  • Participants who have a diagnosis of atopic dermatitis at least 12 months prior to screening as defined by the American Academy of Dermatology
  • Have a history, documented by a physician and/or investigator, of inadequate response to existing topical medications within 6 months preceding screening, or participants who failed systemic therapies intended to treat atopic dermatitis or a history of intolerance to topical therapy
  • Have a body mass index of 18.0 to 38.0 kilograms per square meter (kg/m²), inclusive
  • Male participants who agree to use highly effective or effective methods of contraception, women not of childbearing potential and women of childbearing potential may participate in part B

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant and/or lactating
  • Participants who have received (s) (including attenuated live vaccines) or Bacillus Calmette- Guérin within 35 days of screening
  • Have a history or presence of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs
  • Have a known history of diabetes
  • Have fasting glucose level of ≥126 milligrams per deciliter (mg/dL) and ≥6.5 percent (%) and/or taking anti-diabetes medications at screening
  • Have known history of osteoporosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Part A: LY3872386

    Single doses of LY3872386 (low dose, mid dose, and high dose) administered intravenously (IV) in healthy participants.

    Drug: LY3872386

  • Experimental
    Part B: LY3872386

    Part B was planned but not initiated as study terminated early due to emerging nonclinical data.

    Drug: LY3872386

  • Experimental
    Part C: Prednisone

    Part C was planned but not initiated as study terminated early due to emerging nonclinical data.

    Drug: Prednisone

  • Placebo comparator
    Placebo

    Placebo administered IV in healthy participants.

    Drug: Placebo

Interventions

  • DrugLY3872386

    Administered IV.

  • Administered orally.

  • DrugPlacebo

    Administered IV.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.

    Time frame: Baseline through Day 85

  2. Part B: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.

    Time frame: Baseline through Day 183

  3. Part C: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.

    Time frame: Baseline through Day 44

Secondary outcomes

  1. Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386

    Cmax of LY3872386 is reported.

    Time frame: Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)

  2. PK: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386

    Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) and Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of LY3872386 is reported.

    Time frame: Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)

  3. PK: Part C: Cmax of Prednisone and Prednisolone

    Zero participants were analyzed in this outcome as study was terminated early.

    Time frame: Predose up to 12 hours post dose on day 14 and day 30

  4. PK: Part C: AUC of Prednisone and Prednisolone

    Zero participants were analyzed in this outcome as study was terminated early.

    Time frame: Predose up to 12 hours post dose on day 14 and day 30

07

Results

Posted Oct 3, 2025
Limitations and caveats
Based on the emerging nonclinical data, Study KMAA was terminated after the dosing of participants in SAD Cohorts 1 and 2 (Dose 1 IV and Dose 2 IV) and the sentinel pair in SAD Cohort 3 (Dose 3 IV).

Participant flow

Participant flow — Overall Study
MilestonePart A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: Placebo
Started6615
Received at least one dose of study drug6615
Completed6615
Not completed0000

Outcome measures

PrimaryPart A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.

Time frame:
Baseline through Day 85
Reported as:
Number · participants
Part A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug Administration
participantsPart A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: Placebo IV
TEAEs0200
SAEs0000
AEs0200
PrimaryPart B: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.

Time frame:
Baseline through Day 183

No measurements were reported for this outcome.

PrimaryPart C: Number of Participants With One or More TEAEs, SAEs and Other Non-serious AEs Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug. Zero participants were analyzed in this outcome as study was terminated early.

Time frame:
Baseline through Day 44

No measurements were reported for this outcome.

SecondaryPharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386

Cmax of LY3872386 is reported.

Time frame:
Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386
micrograms per milliliter (µg/mL)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part B: LY3872386
Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY38723862.54 ± 16.97.89 ± 16.3NA ± NA—
SecondaryPK: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386

Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) and Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of LY3872386 is reported.

Time frame:
Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)
Reported as:
Geometric mean · microgram*hour per milliliter(µg*hr/mL)
PK: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386
microgram*hour per milliliter(µg*hr/mL)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part B: LY3872386
AUC(0-tlast) of LY387238655.7 ± 15.6328 ± 19.7NA ± NA—
AUC(0-∞) of LY387238665.8 ± 18.6337 ± 20.3NA ± NA—
SecondaryPK: Part C: Cmax of Prednisone and Prednisolone

Zero participants were analyzed in this outcome as study was terminated early.

Time frame:
Predose up to 12 hours post dose on day 14 and day 30

No measurements were reported for this outcome.

SecondaryPK: Part C: AUC of Prednisone and Prednisolone

Zero participants were analyzed in this outcome as study was terminated early.

Time frame:
Predose up to 12 hours post dose on day 14 and day 30

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to Day 85. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Low Dose LY38723860/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Mid-dose LY38723860/6 (0%)0/6 (0%)3/6 (50%)
Part A: High Dose LY38723860/1 (0%)0/1 (0%)0/1 (0%)
Part A: Placebo0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent other events
Most frequent other events
EventPart A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: Placebo
Upper respiratory tract infectionInfections and infestations0/62/60/10/5
Conjunctival haemorrhageEye disorders0/61/60/10/5
KeratitisEye disorders1/60/60/10/5
Injection site erythemaGeneral disorders0/61/60/10/5
HeadacheNervous system disorders1/61/60/10/5
Menstruation irregularReproductive system and breast disorders0/61/60/10/5

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: PlaceboTotal
<=18 years00000
Between 18 and 65 years661518
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: PlaceboTotal
Female23027
Male431311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: PlaceboTotal
Hispanic or Latino12115
Not Hispanic or Latino540413
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: PlaceboTotal
American Indian or Alaska Native01001
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American30003
White241512
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Part A: Low Dose LY3872386Part A: Mid-dose LY3872386Part A: High Dose LY3872386Part A: PlaceboTotal
United States661518
08

Study locations

2 sites
  • CenExel ACT
    Anaheim, California 92801, United States
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Apr 2024, 5 months.

Results were first posted in Oct 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 7, 2023
StartActual
Nov 1, 2023
Primary completionActual
Apr 8, 2024
CompletionActual
Apr 8, 2024
Results first posted
Oct 3, 2025
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06119529
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Nov 1, 2023
Primary completion
Apr 8, 2024
Completion
Apr 8, 2024
Results posted
Oct 3, 2025
Last update
Oct 3, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion